...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bone Reports >Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study
【24h】

Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study

机译：一项全国性的观察性队列研究显示，高剂量而非低剂量的质子泵抑制剂与第一次髋部骨折后发生随后的髋部骨折的风险增加相关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AimTo examine the association of proton pump inhibitor (PPI) use with subsequent hip fracture incidence in hip fracture patients, accounting for gender, age, PPI doses, PPI initiation before or after first fracture, and year from first fracture in which the first subsequent fracture occurred.MethodsData from 31,668 Austrian patients ≥50?years with the first hip fracture between July 2008 and December 2010 were analyzed retrospectively. After exclusion of patients on anti-osteoporotic medication, incidence of subsequent hip fractures was compared between users and non-users of PPIs using regression models.ResultsIn general, use of PPIs among hip fracture patients was associated with increased risk for subsequent hip fracture (OR 1.58, 95%-CI 1.25–2.00), in particular in men, in the age group of 70–84?years, and when PPIs were initiated before the first fracture. Low PPI doses of ≤90 cumulative DDDs and ≤0.25 DDDs/day, however, were not linked to elevated subsequent fracture risk, especially among female patients. Subsequent hip fracture incidence was elevated within the first year after first fracture in female and male PPI users (OR 1.75, 95%-CI 1.28–2.38) and dropped in women but not in men in the second year.ConclusionsLow-dose PPI use is not associated with increased risk of subsequent hip fractures, especially in women. Patients thus get most benefit of short-term PPI use after a hip fracture that has previously been linked to lowered mortality if low doses are not exceeded. Varying risk profiles for the time of subsequent hip fracture could have implications for risk group-specific follow-up care.
机译：目的探讨质子泵抑制剂（PPI）的使用与髋部骨折患者随后发生的髋部骨折发生率的相关性，并考虑性别，年龄，PPI剂量，第一次骨折前后的PPI起始以及第一次骨折后的第一年（其中第一次随后的骨折）方法回顾性分析2008年7月至2010年12月间31668例≥50岁的奥地利首次髋部骨折患者的数据。在排除使用抗骨质疏松药物的患者后，使用回归模型比较了PPI使用者和非使用者随后发生的髋部骨折的发生率。结果通常，髋部骨折患者中使用PPI会增加随后发生髋部骨折的风险（OR 1.58，95％-CI 1.25-2.00），尤其是男性，年龄在70-84岁，以及第一次骨折之前开始PPI的年龄段。但是，低PPI剂量≤90累积DDDs和≤0.25 DDD / d并不与随后的骨折风险升高相关，特别是在女性患者中。女性和男性PPI使用者第一次骨折后的第一年，其后髋部骨折发生率升高（OR 1.75，95％-CI 1.28–2.38），第二年女性下降，而男性则下降。结论：低剂量PPI的使用是与随后的髋部骨折风险增加无关，特别是在女性中。因此，如果未超过低剂量，先前曾与降低死亡率相关的髋部骨折后，患者将获得短期PPI使用的最大益处。随后发生髋部骨折的风险状况各异，可能会对特定风险组的后续护理产生影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号